Supplementary Figure 2

Cohort 1 (n=10) miR-seq – N-stage marker discovery

Cohort 2 (n=33) RT-qPCR N-stage marker validation

Cohort 1+2+NAT (n=10+33+21=64) RT-qPCR Cancer vs. matched normal comparison

Cohort 3 (n=233) N-stage marker validation in TCGA cohort

Cohort 3 (n=233) prognostic value assessment in TCGA cohort
Supplementary Figure 3
Supplementary Figure 4
Supplementary Figure 6
Supplementary Figure 7

A. Relative expression of miR-31/RNU6B
B. Cell numbers (x200)
C. H2228/miR31 H2228/miRcont
D. OD (450nm)
Supplementary Figure 9

A

H2228

<table>
<thead>
<tr>
<th>miR31</th>
<th>+</th>
<th>+</th>
<th>-</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>miRCont</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>AZD6244</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

P-ERK1/2

ERK1/2

Actin B

B

<table>
<thead>
<tr>
<th>OD (450nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.7</td>
</tr>
<tr>
<td>1.5</td>
</tr>
<tr>
<td>1.3</td>
</tr>
<tr>
<td>1.1</td>
</tr>
<tr>
<td>0.9</td>
</tr>
<tr>
<td>0.7</td>
</tr>
<tr>
<td>0.5</td>
</tr>
</tbody>
</table>

H2228/miR31 | + | + | - | - | - |
H2228/miRCont | - | - | + | + | + |
AZD6244 | + | - | + | - | - |

*<0.001

C

Cell numbers (x200)

H2228/miR31 | + | + | - | - | - |
H2228/miRCont | - | - | + | + | + |
AZD6244 | + | - | + | - | - |

*<0.0005, **<0.005